LifeMD price target lowered to $8 from $12 at KeyBanc

KeyBanc analyst Scott Schoenhaus lowered the firm’s price target on LifeMD (LFMD) to $8 from $12 and keeps an Overweight rating on the shares. The firm notes LifeMD is being impacted by low-cost compounders despite the FDA outlawing the practice earlier this year. However, KeyBanc expects cash prices for brand-name GLP-1s to continue to come down as well as stricter enforcement against compounders in FY26, which should benefit LifeMD due to its partnerships with Eli Lilly (LLY) and Novo (NVO). The firm also expects the launch of oral Wegovy in early FY26 to drive higher weight management subscribers.